In Vitro Antibody Discovery and the Potential Value of AI: The AIntibody Challenge

In Vitro Antibody Discovery and the Potential Value of AI: The AIntibody Challenge A growing number of methods now enable access to rich sequence sets of target-specific antibodies. However, differences in quality, diversity and speed can be difficult to interpret. Tools such as high-throughput surface plasmon resonance (HT-SPR) are proving essential in accessing and understanding these outputs. Join our experts as they explore state of the art library approaches and examine the inaugural AIntibody Challenge, which benchmarked real-world performance and the potential value of AI in antibody discovery. They will also discuss the use of HT-SPR to profile immune repertoires from malaria patients, assess polyreactivity and evaluate antibody binding activity and quality. Attend this webinar to: Discover the power of the in vitro Specifica Generation 3 platform in antibody discovery Understand the effectiveness of AI in antibody affinity maturation and discovery Learn about the use of HT-SPR to provide rich pictures of immune repertoire kinetic and epitope diversity Gain further insights into the use of HT-SPR to identify potential quality issues of antibodies, polyspecificity and specific activity Andrew Bradbury, PhD, MD Chief Scientific Officer, Specifica, an IQVIA business Dan Bedinger, PhD Senior Manager, Field Applications Science, Carterra